Everolimus a derivative of rapamycin, leverages its macrocyclic lactone structure to inhibit mTORC1, a pathway critical both for tumor growth and for type I IFN production, thereby enhancing viral replication and spread. binds FKBP12 to inhibit mTORC1, suppressing cellular proliferation and angiogenesis. While it modulates macrophage activity and cytokine release, it also induces autophagy, contributing to its antitumor effects. Hence its use in combination with OVT. This evidence concerns the gene FKBP1A and neoplasm.